Результаты поиска

Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk.

A cohort of 650 patients treated for localized prostate cancer (PCa) with CyberKnifeTM ultra-hypofractionated radiotherapy between 2011 and 2018 was retrospectively analyzed in terms of survival, patterns of failure, and outcomes of second-line definitive salvage therapies. The analysis was performed using survival analysis including the Kaplan-Meier method and Cox regression analysis. At a median follow-up of 49.4 months, the main pattern of failure was local-regional failure (7.4% in low-, and 13% in intermediate/high-risk group at five years), followed by distant metastases (3.6% in low-, a

Совпадение в полном тексте источника
… Or from the diagnosis of clinical failure (LRC, FFDM) to the occurrence of clinical progression or death after metastases-directed local therapy for second-line progression-free survival (sPFS). Death was defined as all-cause mortality (non-disease-specific). … Second-Line Progression-Free Survival after Definitive Salvage Treatment As described above, the first event regarded as a clinical failure was local recurrence in 23 cases, regional lymph node failure in 15 cases, simultaneous local–regional failure in three cases, and distant metastases in 18 cases …

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma.

OBJECTIVE: This study aimed to identify the clinical significance of TP53 and common cytogenetic abnormalities. MATERIALS AND METHODS: A total of 114 patients with newly diagnosed multiple myeloma (MM) and TP53 abnormalities were selected from two large patient cohorts of collaborating hospitals from 2010 to 2017. The characteristics and outcomes of these patients were analyzed. TP53 and other common mutations in MM patients were quantified by fluorescence in situ hybridization. Kaplan-Meier curves and log-rank tests were applied for survival analysis. A Cox proportional hazard model for cova

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.

Patients with follicular lymphoma (FL) frequently require multiple treatments during their disease course; however, survival based on lines … th FL grade 1-3A managed between 1998 and 2009 at our institution. Median overall survival (OS) and progression-free survival (PFS) after first-line treatment were not reached and 4.73 years, respectively. Following successive lines of treatment, years of median OS and PFS were, respectively: after second-line, 11.7 and 1.5; third-line, 8.8 and 1.1; fourth-line, 5.3 and 0. …

Skin Toxic Effects and Survival With Enfortumab Vedotin-Pembrolizumab in Advanced Urothelial Carcinoma.

IMPORTANCE: Skin toxic effects are a common early adverse event of enfortumab vedotin plus pembrolizumab (EVP) therapy, but its association … MAIN OUTCOMES AND MEASURES: Primary outcome was overall survival (OS). Secondary outcomes included progression-free survival and objective response rate (ORR). OS and PFS were measured from EVP therapy initiation to the respective event or last follow-up. ORR was evaluated among patients with a response assessment after the 30-day landmark, according to skin toxic effects …

Apatinib in combination with docetaxel and S-1 chemotherapy as first-line treatment for metastatic gastric cancer.

This study aimed to evaluate the efficacy and safety of apatinib, an oral VEGFR2 tyrosine kinase inhibitor, combined with docetaxel and S-1 … to 6 planned cycles. 45 patients were enrolled, with a median follow-up time of 12.4 months. Median progression-free survival (PFS) and overall survival (OS) were 7.6 months (95% CI: 5.8%-9.4%) and 12.4 months (95% CI: 9.3%-15.5%), respectively in the full analysis set. Patients completing ≥4 cycles achieved a better mOS of 14.5 months (95% CI: 12.0%-17.1%). The objective …

Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.

BACKGROUND: For patients with left-sided metastatic colorectal cancer (mCRC), the recommended first-line treatment is anti-epidermal growth … patients were divided into two groups: the cetuximab and panitumumab groups. Overall survival (OS), progression-free survival (PFS), and response rate (RR) were compared between the two groups. RESULTS: A total of 233 patients were enrolled: 87 (37.3%) in the cetuximab group and 146 (62.7%) in the panitumumab group. Median OS, PFS, and RR of the cetuximab and panitumumab …

Exploratory Investigation Into Perioperative Treatment Strategies for Potentially Resectable Stage III-N2 Driver Gene-Negative Non-Small Cell Lung Cancer in the Immunotherapy Era.

BACKGROUND: Comparisons among treatment strategies for potentially resectable Stage III-N2 driver gene-negative non-small cell lung cancer ( … II-N2 NSCLC from two institutions (2019-2024) were retrospectively enrolled. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Subgroup analyses included metastatic N2 lymph node status, stage, programmed death ligand 1 expression, radiographic response to NCIT, and adjuvant or consolidation immunotherapy after surgery or CRT. Baseline diffe …

Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy.

PURPOSE: Immune checkpoint inhibitor plus chemotherapy is the standard first-line treatment for advanced gastric cancer; however, predictive … ons per megabase and 18.19%, respectively, as determined based on their ability to best distinguish progression-free survival (PFS) among the patients who received nivolumab plus chemotherapy. RESULTS: PFS was favorable for nivolumab and chemotherapy than for chemotherapy alone in both the high and low TMB groups; nevertheless, survival benefits were observed only in the …

The good, the bad, and the manageable: real-world outcomes with CDK4/6 inhibitors.

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy represent the standard of care for hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC). While clinical trials established their efficacy, real-world evidence on safety, dose adjustments, and outcomes remains limited. We conducted a prospective observational study including patients with HR+/HER2- mBC treated with palbociclib, ribociclib, or abemaciclib across three oncology units between 2019 and 2024. Data on adverse events, dose modifications, progression-free survival (PFS), and …

Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer.

Netrin1, a developmental cue, is a master regulator of tumour epithelial-to-mesenchymal transition (EMT)1, a mechanism that is known to driv … eived mFOLFIRINOX plus NP137 every other week for up to 12 cycles. NP137 was well tolerated. Median progression-free survival (PFS) was 10.85 months (95% confidence interval, 10.03-15.61) and median overall survival was 16.43 months (95% confidence interval, 12.75-non-reached), with 21 patients remaining alive at the time of data cut-off. Post-therapy conversion surgery oc …

Real-World Evidence on Preoperative Targeted Therapy for Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus.

BACKGROUND: Previous evidence, predominantly from case studies and small cohort series, has indicated that targeted therapy can induce downg … condary endpoints included thrombus length reduction, objective response rates (ORRs; RECIST v1.1), progression-free survival (PFS), and treatment-related adverse events (TRAEs); Common Terminology Criteria for Adverse Events version 5.0. Associations between baseline clinical/radiological-parameters and IVC-TT downgrading were further analyzed. RESULTS: The cohort had a …

Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers.

PURPOSE: Epidermal growth factor receptor (EGFR) amplification remains a controversial therapeutic biomarker. We report outcomes of erlotini … as the clinical benefit rate (CBR), while secondary endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Between February 2021 and April 2024, 25 patients were treated with E + B (median EGFR copy 8.9; range, 3-76). Six tumor types were included, with colorectal cancer being the most prevalent (N = 14 …

Pazopanib combined with doxorubicin and cisplatin in recurrent osteosarcoma: A retrospective cohort study.

Treatment options for recurrent osteosarcoma remain limited, and prognosis is poor. Pazopanib, a multi-targeted tyrosine kinase inhibitor, h … using response evaluation criteria in solid tumors (RECIST 1.1) criteria. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate, disease control rate, safety, and treatment compliance. Baseline characteristics were well balanced between groups (P > .05). The Paz + AP group achieved a higher di …

Long-Term Outcomes of Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Patients With Systemic Sclerosis With Impaired Cardiac Function.

OBJECTIVE: High-intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with adva … difying antirheumatic drugs or worsening end-organ failure. We determined overall survival (OS) and progression-free survival (PFS) by the Kaplan-Meier method and identified pretransplant characteristics associated with OS or PFS by multivariable Cox regression. RESULTS: All participants had evidence of SSc with cardiac involvement. Ninety-five percent of participants had …

[177Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial.

BACKGROUND/AIM: To evaluate the efficacy of [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) plus capecitabine and temozolomi … s 1-14 and TEM 75 mg/m2 b.i.d. Days 10-14. CAPTEM Q 4 weekly (pNET control arm). PRIMARY ENDPOINT: Progression-free survival (PFS) @ 15 months (SBNETS) (target > 80%), and 12 months (pNETs) (target >75%). Other: Objective response rate (ORR), overall survival and adverse events (AE). Extended follow-up was undertaken after initial analysis. RESULTS: Seventy-two patients …

Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study.

Here we report the efficacy and translational findings of durvalumab, olaparib, and cediranib (D + O + C) and of durvalumab plus cediranib (D + C) from the recurrent ovarian cancer cohort within a single-center, multi-arm, non-randomized, multi-cohort phase I/II trial (NCT02484404). Sixty-eight patients were enrolled (39 in D + O + C, 29 in D + C). The primary endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS) and safety. ORR was 19.4% (95% CI, 9.5-43.5) for D + O + C and 29.6% (95% CI, 13.8-46.9) for D + C; D + C met the primary endpoint w…

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3.

INTRODUCTION: Elranatamab, approved for relapsed or refractory multiple myeloma, demonstrated deep, durable responses and manageable safety … .6% (95% CI, 28.3-57.8) achieved complete response or better. Median (95% CI) duration of response, progression-free survival, and overall survival were 40.8 (24.0-not estimable [NE]), 27.3 (4.3-NE), and 43.6 (14.9-NE) months, respectively. Common (≥60%) treatment-emergent adverse events (any grade; grade 3/4) included infections (70.2%; 42.6%), fatigue (61.7%; 8.5%), and …

Chemotherapy combined targeted therapy has a potential benefit on the survival of advanced intrahepatic cholangiocarcinoma.

The treatment strategies and outcomes for advanced intrahepatic cholangiocarcinoma (ICC) are restricted. The treatment modalities and effectiveness of local interventional chemotherapy and systemic chemotherapy remain indeterminate. The objective of this study is to explore and assess the influence of different chemotherapy methods on the prognosis of patients with advanced ICC. A retrospective investigation was carried out at two research centers. The recruited patients were divided into the systemic chemotherapy cohort and the local chemotherapy cohort (Transarterial Chemoembolization, TACE)

Enfortumab Vedotin-Induced Cutaneous Toxic Effects and Survival in Urothelial Carcinoma.

IMPORTANCE: Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of locally advanced or metastatic urothelial cancer. Cutaneous adverse events (cAEs) are common during EV therapy, with prior studies suggesting an association between EV-related cAEs and improved survival; however, there are insufficient data to delineate the survival benefit of EV-induced cAEs from those associated with concurrent immune checkpoint inhibitors (ICIs). OBJECTIVE: To evaluate the association of EV-induced cAEs with survival and to characterize the timing and morphologic mechanisms of E

Association Between Immune-Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective Study.

BACKGROUND: Immune-related adverse events (irAEs) have been linked to improved outcomes in patients undergoing treatment with immune checkpo … tients were stratified into two groups based on the occurrence of irAEs. Outcomes, including OS and progression-free survival (PFS), were compared using Kaplan-Meier analysis, landmark analysis, and Cox proportional hazards regression. RESULTS: Among the 60 patients analyzed, 15 (25%) developed irAEs of any grade, with 3 patients (5%) experiencing grade ≥ 3 irAEs. Patient …